Pharma omics virtual seminar – Now on demand

Chronic haloperidol treatment leads to an imbalance of synaptic excitation and inhibition of D1-MSN neurons, presented by Bruno Manadas

Haloperidol is a strong antipsychotic and has high efficacy against the positive symptoms of Schizophrenia, however no efficacy against negative or cognitive symptoms has been proven. Although dopamine D₂ receptor blockade can be achieved within hours after haloperidol administration, the onset of action is delayed by weeks. Using proteomic analysis and whole-cell patch-clamp recordings of the striatum of mice chronically exposed to HA, we demonstrate a possible mechanism by which haloperidol may be contributing to its beneficial long-term therapeutic effect.

Introducing the ZenoTOF 7600 system; revealing new perspectives for biomarkers research, presented by Heather Chassaing, SCIEX

In this presentation, we will introduce the ZenoTOF 7600 System. It combines two new innovations, the first is the Zeno trap which enhances the quality and intensity of MS/MS spectra allowing the detection and characterization of low level metabolites.  The second is the choice of an alternative fragmentation technology Electron Activated Dissociation (EAD), to achieve greater depths in structural elucidation and isomer differentiation.  We will discuss how by combining these two new technologies we can answer the challenging questions encountered in metabolomic workflows.

Functional proteomics in discovery and translational medicine - part 1, presented by Nikolaus Berndt

In part 1 of this 2-part session, we’ll look at SWATH-based metabolic profiling of cells and tissue samples. You will learn about the benefits of using QSM (quantitative system metabolism) technology for animal model characterization, functional classification and disease stratification.

Functional proteomics in discovery and translational medicine - part 2, presented by Jan Detmers

In part 2 of this 2-part session, we’ll look at deep metabolic profiling in oncology, immunology, neurology, metabolic disorders and toxicology. You will learn about the latest QSM case studies in preclinical science and clinical trial support.

Robust and ultra-sensitive bioanalysis using the SCIEX 7500 system, presented by Jack Steed, SCIEX

In this presentation, we will cover the analysis of glucosylsphingosine (GluSPH) and galactosylsphingosine (GalSPH) in cerebral spinal fluid, highlighting the sensitivity increase achieved with the SCIEX 7500 system when compared with the SCIEX Triple Quad 6500+ system. We’ll also see how increased sensitivity allows for a smaller volume of cerebral spinal fluid to be used for analysis, increasing the number of assays that can be performed using a single sample. Finally, we’ll discover the high levels of robustness available when using the SCIEX 7500 system over 1,500 plasma sample injections.

Metabolomics for translational drug research and strategies for personalized health, presented by Thomas Hankemeier

In this presentation several approaches and examples of the use of metabolomics for translational drug research are presented. Different analytical methods will be presented, and how these can be used for prevention.